{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.6","upperLimit":"54.8","value":"54.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\n\n\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\n\n\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\n\n\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}